CD274 and non-small cell lung carcinoma: In front line management of advanced NSCLC, the Keynote 024 trial concluded that patients with tumors expressing ≥50% PD-L1 derive greater clinical outcomes with pembrolizumab, a PD-1 immune checkpoint inhibitor (ICPI), than with platinum-based chemotherapy, both in terms of response rate (44.